{"preliminary_commentary":{"by_channel":{"x_thread":9},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05223803\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"TERPS","nct_id":"NCT05223803","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=terps-nct05223803. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Best systemic therapy (BST) + primary prostate radiation (XRT)","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"BST + XRT + SABR metastasis-directed therapy (MDT)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-07-31","type":"ESTIMATED"},"conditions":["Prostate Cancer","Oligometastatic Disease"],"enrollment":{"count":122,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Prostate radiation (XRT)","otherNames":[],"type":"RADIATION"},{"name":"Systemic Therapy","otherNames":[],"type":"DRUG"},{"name":"Stereotactic ablative radiation therapy (SABR)","otherNames":[],"type":"RADIATION"}],"last_update":"2026-06-03","lead_sponsor":"University of Maryland, Baltimore","official_title":"Phase 2 Randomized Total Eradication of Metastatic Lesions Following Definitive Radiation to the Prostate in de Novo oligometaStatic Prostate Cancer (TERPS) Trial","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-07-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To determine the 2-year failure-free survival (FFS) of men who have oligometastatic prostate cancer with BST+XRT versus BST+XRT+SABR MDT.","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2022-10-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"TERPS Trial for de Novo Oligometastic Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT05223803"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/terps-nct05223803"}